PRESS RELEASE published on 06/24/2024 at 07:30, 2 months 25 days ago OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T OSE Immunotherapeutics annonce un accord avec le Memorial Sloan Kettering Cancer Center pour les thérapies CAR-T. L'accord porte sur des brevets dans le traitement des cancers exprimant l'IL-7R Brevets OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center IL-7R Thérapies CAR-T
PRESS RELEASE published on 06/24/2024 at 07:30, 2 months 25 days ago OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
BRIEF published on 06/20/2024 at 07:35, 2 months 29 days ago OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress Autoimmune Diseases OSE Immunotherapeutics FOCIS 2024 IL-35 Therapeutic MRNA
BRIEF published on 06/20/2024 at 07:35, 2 months 29 days ago OSE Immunotherapeutics présente des données prometteuses sur la plateforme ARNm au congrès FOCIS Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique FOCIS 2024 IL-35
PRESS RELEASE published on 06/20/2024 at 07:30, 2 months 29 days ago OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin) OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique au congrès annuel FOCIS à San Francisco. L'IL-35 joue un rôle clé dans le contrôle des maladies auto-immunes et inflammatoires Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique IL-35 FOCIS
BRIEF published on 06/05/2024 at 07:35, 3 months 14 days ago OSE Immunotherapeutics and Nantes University Hospital Present Positive Results in Renal Transplantation Immunotherapy Clinical Test OSE Immunotherapeutics FR104/VEL-101 Kidney Transplantation
BRIEF published on 06/05/2024 at 07:35, 3 months 14 days ago OSE Immunotherapeutics et le CHU de Nantes Présentent des Résultats Positifs en Transplantation Rénale Immunothérapie Essai Clinique OSE Immunotherapeutics Transplantation Rénale FR104/VEL-101
PRESS RELEASE published on 06/05/2024 at 07:30, 3 months 14 days ago OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant OSE Immunotherapeutics and Nantes University Hospital present positive Phase 1/2 study evaluating FR104/VEL-101 immunotherapy in renal transplant at American Transplant Congress 2024 Immunotherapy Phase 1/2 Study OSE Immunotherapeutics Nantes University Hospital Renal Transplant
PRESS RELEASE published on 06/05/2024 at 07:30, 3 months 14 days ago OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale OSE Immunotherapeutics et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l'essai clinique de Phase 1/2 évaluant l'immunothérapie FR104/VEL-101 en transplantation rénale au congrès 'American Transplant Congress' 2024 Essai Clinique OSE Immunotherapeutics Transplantation Rénale FR104/VEL-101 Centre Hospitalier Universitaire De Nantes
BRIEF published on 05/22/2024 at 07:35, 3 months 28 days ago OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour de nouveaux traitements Collaboration Immunothérapie Cancer Cardio-rénal-métabolique
Published on 09/19/2024 at 17:30, 28 minutes ago Airborne Geophysical Survey Completed at Pine Channel Gold Project, Saskatchewan
Published on 09/19/2024 at 17:00, 58 minutes ago Cypress Creek Consulting Advises Charter Communications on Inaugural Securitization Financing Facility
Published on 09/19/2024 at 15:45, 2 hours 13 minutes ago eLearners Make eLearning a Daily or Weekly Habit, Voices' eLearning Report Finds
Published on 09/19/2024 at 15:20, 2 hours 38 minutes ago Taurus secures "Best Digital Assets Solution" at 2024 Global BankTech Awards
Published on 09/19/2024 at 15:01, 2 hours 57 minutes ago ful. CashPay: Revolutionizing Healthcare Access for Employers With Uninsured Team Members
Published on 09/19/2024 at 17:45, 12 minutes ago AFG Holding SA acquiert une participation majoritaire dans le groupe allemand Access Holding et prend ainsi le contrôle de
Published on 09/19/2024 at 17:09, 48 minutes ago Adler Group S.A. announces the completion of the comprehensive recapitalisation
Published on 09/19/2024 at 17:00, 57 minutes ago EQS-Adhoc: SMT Scharf AG: Yankuang new strategic core shareholder
Published on 09/19/2024 at 15:10, 2 hours 47 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 09/19/2024 at 15:08, 2 hours 49 minutes ago Form 8.3 - The Vanguard Group, Inc.: Ascential plc
Published on 09/19/2024 at 17:45, 13 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 13 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 13 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)